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Abstract
Background: Chronic lymphocytic leukemia (CLL) is a highly variable disease with life expectancies ranging from
months to decades. Cytogenetic findings play an integral role in defining the prognostic significance and
treatment for individual patients.
Results: We have evaluated 25 clinical cases from a tertiary cancer center that have an established diagnosis of
CLL and for which there was prior cytogenetic and/or fluorescence in situ hybridization (FISH) data. We performed
microarray-based comparative genomic hybridization (aCGH) using a bacterial artificial chromosome (BAC)-based
microarray designed for the detection of known constitutional genetic syndromes. In 15 of the 25 cases, aCGH
detected all copy number imbalances identified by prior cytogenetic and/or FISH studies. For the majority of those
not detected, the aberrations were present at low levels of mosaicism. Furthermore, for 15 of the 25 cases,
additional abnormalities were detected. Four of those cases had deletions that mapped to intervals implicated in
inherited predisposition to CLL. For most cases, aCGH was able to detect abnormalities present in as few as 10% of
cells. Although changes in ploidy are not easily discernable by aCGH, results for two cases illustrate the detection
of additional copy gains and losses present within a mosaic tetraploid cell population.
Conclusions: Our results illustrate the successful evaluation of CLL using a microarray optimized for the
interrogation of inherited disorders and the identification of alterations with possible relevance to CLL
susceptibility.
Background
B-cell chronic lymphocytic leukemia (CLL) is the most
common of the leukemias, accounting for ~30% of all
cases [1]. CLL exhibits a highly variable course with life
expectancies ranging from only a few months to many
decades. Cytogenetic evaluation is a key component in
the diagnosis of this disorder and, importantly, in defin-
ing the prognostic significance of the disease and opti-
mal treatment choices for individual patients. The most
common cytogenetic aberrations identified through con-
ventional karyotyping and fluorescence in situ hybridiza-
tion (FISH) are deletion 13q14, deletion 6q, trisomy 12,
deletion 11q22q23 and deletion 17p13. More than 80%
of patients show one or more of these alterations by
chromosome analysis, with approximately the same
number seen by FISH. These recurrent cytogenetic
abnormalities have prognostic significance as they are
associated with an increasingly poorer outcome in the
order listed [2-4]. Thus, deletion of 13q14, which is the
most common finding and is seen in 57% of cases ana-
lyzed by FISH and 55% by chromosome analysis [3], is
associated with a favorable prognosis, whereas the poor-
est prognostic indication by cytogenetics, deletion of the
TP53 gene at 17p13, is seen in only 7% of FISH cases.
Microarray analysis has been well established for the
genetic diagnosis of chromosomal disorders, and it was
recently proposed that this technology be used as a
first-tier test for a majority of children with clinical indi-
cations suggestive of a cytogenetic abnormality [5]. The
use of arrays in the evaluation of hematologic malignan-
cies is rapidly gaining use in response to the need for
significantly greater molecular resolution to aid in diag-
nostic, prognostic and individualized decisions. In the
case of pediatric acute lymphoblastic leukemia (ALL),
microarrays have allowed for the identification of
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any medium, provided the original work is properly cited.additional aberrations that are well below the limits of
resolution for conventional cytogenetics and the deter-
mination of the prognostic significance for such findings
[6-8]. Microarray studies using bacterial artificial chro-
mosome (BAC)- or oligonucleotide (oligo)-based micro-
arrays for the analysis of CLL have recently been
described [9-11]. One study examining 174 CLL cases
utilized a BAC array comprised of clones targeted to
CLL-relevant loci and further defined abnormalities with
higher-density oligonucleotide arrays and FISH [10]. For
89% of the cases, alterations were detected with the
BAC arrays, and the limit of detection for clonal altera-
tions was estimated to reside around 30%. An additional
study showed that an appropriately designed microarray
can detect clinically relevant findings that would
be missed using FISH panels [9]. Recently, a few
studies have demonstrated the use of single-nucleotide
polymorphism (SNP) microarrays for the detection of
chromosome aberrations [12,13]. In one study, a cross-
platform comparison demonstrated the robustness of
BAC arrays compared to SNP microarrays, which had
relatively high levels of technical variation [12]. Accord-
ingly, comparative genomic hybridization (CGH)-based
arrays (e.g., BAC and oligo) are still likely the most
appropriate platform for diagnostic use. Thus, microar-
rays offer value for diagnostic and prognostic determina-
tions related to CLL, although precisely how such data
will best be used in conjunction with established cytoge-
netic and FISH criteria has yet to be determined.
In this study we evaluated CLL cases using a whole-
genome BAC microarray platform with increased coverage
over regions of the genome associated with constitutional
genetic syndromes and subtelomeric and pericentromeric
regions. The results suggest that both CLL and CLL-
predisposing microdeletions are readily detectable by
microarray analysis.
Methods
Specimen ascertainment
Upon institutional review board approval (IRB 07245,
04187, 95124), we queried the City of Hope cytogenetic
database to identify 33 patients with clinical indications
of CLL and mantle cell lymphoma, who had residual
material available for study.
The results of microarray analysis were compared to
the patients’ corresponding clinical, cytogenetic and
pathological characteristics.
Cytogenetics and FISH validation studies
Cytogenetic and FISH studies were performed using stan-
dard methods. The cytogenetics results were reviewed to
confirm the karyotypic diagnosis, number of secondary
karyotypic changes, and overall karyotype complexity.
Whenever possible, at least 20 mitotic cells were analyzed,
and the non-random cytogenetic aberrations were
described according to ISCN (2009) [14]. Many of the
aberrations observed by conventional cytogenetics were
confirmed by FISH studies for follow-up minimal residual
disease (MRD) testing using standard methods. Two-hun-
dred cells were scored for interphase FISH (I-FISH).
Microarray analyses
DNA was isolated from frozen buffy coat specimens
using the EZ1 tissue kit and robot (Qiagen, Inc., Valen-
cia, CA) per manufacturer’s protocol. After isolation,
DNA concentrations and quality were evaluated by
spectrophotometry using the NanoDrop ND-1000
(NanoDrop Technologies, Wilmington, DE) and by agar-
ose-gel electrophoresis. Microarray-based comparative
genomic hybridization (aCGH) was performed using the
SignatureChip
® Whole Genome™ (SignatureChipWG)
BAC microarray using previously described methods
[15]. Results were visualized using Signature’s laboratory-
developed computer software program Genoglyphix™
(http://www.signaturegenomics.com/genoglyphix.html).
The nucleotide positions listed in SignatureChipWG
v1.0.1 are based on the UCSC Genome Browser’s March
2006 human reference sequence (hg18; NCBI Build 36.1).
The aCGH results were described according to ISCN
2009 [14]. Normal (non-pathogenic) copy number var-
iants (CNV) were not included in the aCGH results
(Database of Genomic Variants, http://projects.tcag.ca/
variation/.).
Statistical analysis
The demographic and clinical covariates were compared
using ANOVA for continuous variables and Fisher’s
exact test for categorical responses.
Results
Case selection for study
DNA was extracted from 33 bone marrow samples. Of
these, 25 had a confirmed diagnosis of CL,L and five
had mantle cell lymphoma. An additional three samples
had insufficient DNA to perform microarray analysis. Of
the 25 samples with CLL, 23 had prior chromosome
analysis, and all had been examined by FISH for part or
all of the CLL FISH panel (Table 1 and 2). Of the 25
cases evaluated, prior FISH evaluation showed that
seven (28%) had deletion of the ATM gene, 12 (48%)
had deletion at 13q14, seven (28%) had deletion of the
TP53 gene, and five (20%) had trisomy 12. The distribu-
tion of abnormalities among the cases proved somewhat
skewed toward the poorer prognostic indicators, given
that trisomy 12 and TP53 deletions are typically less
common (14% and 7%, respectively).
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Case Karyotype FISH Percent
Abnormal
by FISH
Array Results Size
1 46,XY,del(11)(q21q23.3)[6]/46,XY[12] nuc ish(CCND1,IGH@)x2 [217/217]
nuc ish(CD82x2),(ATMx1)[138/200]
nuc ish(CD82x2),(ATMx0)[29/200]
nuc ish(pBR12,APAF1)x2[209/209]
nuc ish(D13S319x1),(LAMP1x2)[129/
200]
nuc ish(TP53,ERBB2)x2[200/200]
0
69
14.5
0
64.5
0
del chr11:90634258-113746962 (11q14.3q23.2)
del chr13:47624176-49406099 (13q14.2q14.3)
del chr11:47479616-49590709 (11p11.2p11.12)
del chr11:84811642-86481659 (11q14.1q14.2)
23.1 Mb
1.8 Mb
2.1 Mb
1.7 Mb
2 46,XX,der(3)del(3)(p13p21)inv(3)(p21p24),der(6)del(6)
(q15q21)inv(6)(p21.3q23)[13]/46,XX[7]
nuc ish(CD82,ATM)x2[200/200]
nuc ish(D13S319x1),(LAMP1x2)[157/
200]
IGH postive with 149/200 (74.5%)
positive with loss of 5’ signal in
majority of cells.
0
78.5
del chr13:48903923-49406099 (13q14.3q14.3)
del chr14:105267349-106339477 (14q32.33q32.33)
dup chr1:912529-3454889 (1p36.33p36.32)
del chr3:23938864-24184494 (3p24.2p24.2)
del chr3:36967519-37301610 (3p22.2p22.2)
del chr3:38387176-38681540 (3p22.2p22.2)
del chr6:31007155-31476070 (6p21.33p21.33)
del chr6:43741228-45692992 (6p21.1p12.3)
del chr6:65600819-65840071 (6q12q12)
del chr6:95941606-99824130 (6q16.1q16.2)
del chr6:106626906-116596208 (6q21q22.1)
dup chr13:113525857-113954547 (13q34q34)
dup chr20:59074507-62317284 (20q13.33q13.33)
del chr22:21330008-21570697 (22q11.22q11.22)
502 kb
1.1 Mb
2.5 Mb
246 kb
334 kb
294 kb
469 kb
2.0 Mb
239 kb
3.9 Mb
10.0 Mb
429 kb
3.2 Mb
241 kb IGL
5 42,X,-X,t(1;9)(q25;p13),add(5)(p13),der(8)t(8;13)(q13;q14),-9,
der(12)t(12;?14) (q13;q11.2),
-13,inv(14)(q11.2q32),
psu dic(15;3)(p11.2;q27),der(17;21)(q10;q10),+der(17)t
(17;21)(q10;q10)del(17)(q25)[15]/45,XX,t(1;10)(q21;q22),add
(3)(q21),t(4;21)(q25;p11.2),t(6;19)(q21;p13.1),-9,del(9)
(p13p24),inv(14)(q11.2q32), psu dic(15;3)(p11.2;q27),der
(17;21)(q10;q10),+21[3]
43,XX,t(2;16)(q13;q22),del(7)(q22q32),der(8)t(8;13)(q13;q14),-
9,add(9)(p13),der(12)t(12;?14)(q13;q11.2),
inv(14)(q11.2q32),psu dic(15;3)(p11.2;q27),der(17;21)(q10;
q10)del(17)(q25),+der(17;21)(q10;q10)add(21)(q22)[2]
nuc ish(TP53x1),(ERBB2x2)[139/200]
nuc ish(TP53x1),(ERBB2x3)[9/200]
69.5
4.5
del chr17:0-21055067 (17p13.3p11.2)
dup chr17:23775933-78654742 (17q11.2q25.3)
dup chr1:912529-3548139 (1p36.33p36.32)
del chr1:221094574-222727272 (1q41q42.12)
del chr1:229351994-229691388 (1q42.2q42.2)
del chr3:115404001-124892494 (3q13.31q21.1)
dup chr3:127341829-129920493 (3q21.2q21.3)
del chr3:133426459-133822407
(3q22.1q22.1)
dup chr3:136891829-139071546 (3q22.3q23)
del chr3:173687986-180776184 (3q26.3126.33)
del chr5:1371093-12586305 (5p15.33p15.2)
del chr8:77643686-79802767 (8q21.11q21.12)
del chr8:115351618-115731259 (8q23.3q23.3)
del chr9:188707-27863525 (9p24.3p21.2)
del chr9:38261089-119714054 (9p13.1q33.1 )
dup chr12:2267492-5164844 (12p13.33p13.32)
del chr12:84097500-132289534 (12q21.31q24.33)
dup chr21:14429720-46912065
(21q11.2q22.3)
del chr22:21044595-21570697 (22q11.22q11.22)
del chrX:32390785-154763822 (Xp21.1q28)
21.1 Mb
54.9 Mb
2.6 Mb
1.6 Mb
339 kb
10 Mb
2.6 Mb
396 kb
2.2 Mb
7.1 Mb
11.2 Mb
2.2 Mb
380 kb
27.7 Mb
81.5 Mb
2.9 Mb
48.2 Mb
Trisomy
526 kb
122 Mb
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4Table 1 Cases in which microarray analysis detected aberrations identified by chromosome analysis or FISH?†? (Continued)
6 46,XY,t(4;13)(q31.3;q14),del(11)(q13q23)[13]/46,XY[7] nuc ish(CD82x2),(ATMx1)[20/200]
nuc ish(TP53,ERBB2)x2[199/200]
10.0
0
del chr13:46386690-49406099 (13q14.2q14.3)
del chr11:49408635-49590709 (11p11.12p11.12)
del chr3:166401814-166712788
(3q26.1q26.1)
del chr11:79505241-113746962 (11q14.1q23.2)
del chr14:105267349-106339477 (14q32.33q32.33)
del chr22:21330008-21570697 (22q11.22q11.22)
3.0 Mb
182.1 kb
311 kb
34.2 Mb
1.1 Mb
241 kb
9 46,XY,del(11)(q13q23)[4]/
46,XY[16]
nuc ish(D11Z1x2),(ATMx1)[12/211]
nuc ish(DDIT3)x2[204/204]
nuc ish(D13S319x1),(LAMP1x2)[10/
200]
nuc ish(CCND1,IGH@)x2[215/215]
nuc ish(TP53x2),17cen(x2)[197/200]
5.7
0
5.0
0
0
del chr11:79505241-106371868 (11q14.1q22.3)
del chr13:46386690-48065782 (13q14.2q14.2)
26.9 Mb
1.7 Mb
11§ 45,XY,t(1;6)(p34.3;p23),der(14)?inv(14)(q22q32)t(8;14)(q21.2;
q32.3),psu dic(20;17)(p12;p11.2)[2]/45,sl,der(9)t(8;9)(q22;
q34)[3]/44,sdl1,-4,der(18)t(4;18)(q12;p11.2)[2]/
88,sdl2x2,+9,+9,-der(9)t(8;9)(q22;q34)x2[cp5]/46,XY[8]
nuc ish(D11Z1,ATM)x4[74/213]
nuc ish(DDIT3)x4[72/250]
nuc ish(D13S319,LAMP1)x4[60/269]
nuc ish(CCND1,IGH@)x4[75/200]
nuc ish(TP53x1),17cen(x2)[55/200]
nuc ish(TP53x2),17cen(x4)[67/200]
34.7
28.8
22.3
62.5
27.5
33.5
del chr4:12959459-96181870 (4p15.33q22.3)
dup chr8:86064184-146236298 (8q21.2q24.3)
del chr13:46386690-47967723 (13q14.2q14.2)
del chr14:87377280-94457872 (14q31.3q32.13)
del chr15:34882707-41330584 (15q14q15.2)
del chr17:1-21055067 (17p13.3p11.2)
del chr18:140284-5368662 (18p11.32p11.31)
del chr20:9944-7553629 (20p13p12.3)
dup chr20:16086026-19632379 (20p12.1p11.23)
del chr22:21330008-21570697 (22q11.22q11.22)
83.2 Mb
60.2 Mb
1.6 Mb
7.1 Mb
6.5 Mb
21.1 Mb
5.23 Mb
7.5 Mb
3.6 Mb
240 kb IGL
12 47,XX,+12[2]/
47,+12,t(2;14)(p13;q32.1)[5]/46,XX[15]
nuc ish(CD82,ATM)x2[262/263]
nuc ish(pBR12,APAF1)x3 [91/200]
nuc ish(D13S319,LAMP1)x2[203/204]
nuc ish(CCND1,IGH@)x2[224/224]
nuc ish(TP53,ERBB2)x2[200/200]
0
45.5
0
0
0
dup chr12:74345-132349534 Trisomy
13 46,XY,der(1)del(1)(p21p32)t(1;11;3)(q23;q23;q23),t(1;11;3)
(q23;q23;q23)[4]
Constitutional Cell Line: 46,XY[15]
nuc ish(CD82,ATM)x2[199/200]
nuc ish(MLLx2)[209/209]
nuc ish(Pbr12,APAF1)x2[200/200]
nuc ish(D13S319,LAMP1)x2[210/211]
nuc ish(TP53,ERBB2)x2[200/200]
0
0
0
0
0
del chr1:63608956-78245151 (1p31.3p31.1)
del chr1:96795246-110397675 (1p21.3p13.3)
del chr1:118792737-119283944 (1p12p12)
dup chr17:9926840-10302007 (17p13.1p13.1)
14.6 Mb
13.6 Mb
491 kb
375 kb
14§ 90 < 4n > XXYY,+3,add(9)(p13)x2,der(12)t(11;12)(q13;
q24.3)x2,add(17)(p11.2)x2,-18,-18,-19[3]/
90,sl,add(1)(p32),del(?15)(q11.2)[5]/87,sdl1,-add(1)(p32),-3,-6,
del(14)(q24)[2]/46,XY[10]
nuc ish(CD82x4),(ATMx6)[112/219]
nuc ish(pBR12,APAF1)x2[65/243]
nuc ish(pBR12,APAF1)x4[178/243]nuc
nuc
nuc ish(D13S319,LAMP1)x4[135/208]
nuc ish(CCND1x6)[13/220]
nuc ish(CCND1x6),(IGH@x4)[127/220]
nuc ish(TP53x2),(ERBB2x4)[139/200]
nuc ish(CCND1,IGH@)x2[112/200]
IGH break-apart showed 15.5% with
normal pattern (2F), 6.2% with a 4F
pattern, 55.9%
with 2F/2R pattern, 22.4% with a 2F/
1R (sdl 2) pattern.
51.1
73.3
64.9
5.9
57.7
69.5
dup chr11:66842920-134431368 (11q13.1q25)
del chr17:1-22098241 (17p13.3p11.2)
del chr1:912529-45151506 (1p36.33p34.1)
dup chr2:44073-64590503 (2p25.3p14)
dup chr3:46141-199230435
dup chr8:117699992-120401821 (8q23.3q24.1)
del chr9:22407649-22847775 (9p21.3p21.3)
dup chr10:3607230-9585338 (10p15.2p14)
del chr12:122218562-132289534 (12q24.31q24.33)
del chr14:105267349-106339477 (14q32.33q32.33)
del chr15:22577151-100126412
del chr18:140284-46969866 (18p11.32q21.2)
del chr19:211754-63770533
67.6 Mb
22.1 Mb
44.2 Mb
65.5 Mb
Trisomy
2.7 Mb
440 kb
6.0 Mb
10.1 Mb
1.1 Mb
Monosomy
46.8 Mb
Monosomy
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4Table 1 Cases in which microarray analysis detected aberrations identified by chromosome analysis or FISH?†? (Continued)
15 46,XY,del(11)(q21q23)[3]/
46,XY[24]
nuc ish(D13S319,LAMP1)x2[99/200]
nuc ish(CD82x2),(ATMx1)[14/200]
0
7.0
del chr11:90736134-113746962 (11q14.3q23.2)
del chr5:141914285-145952287 (5q31.3q32)
del chr16:21509120-21698983 (16p12.2p12.2)
23.0 Mb
4.0 Mb
190 kb
19 47,XY,+12[17]/46,XY[3] nuc ish(CD82,ATM)x2[200/200]
nuc ish(pBR12,APAF1)x3[172/200]
nuc ish(D13S319,LAMP1)x2[216/216]
nuc ish(CCND1,IGH@)x2[212/212]
nuc ish(TP53,ERBB2)x2[200/200]
0
86.0
0
0
0
dup chr12:74345-132289534
del chr2:219234883-220344370 (2q35q35)
del chr14:72506787-72834048 (14q24.2q24.2)
del chr14:105267349-106339477 (14q32.33q32.33)
Trisomy
1.1 Mb
327 kb
1.1 Mb
IGH
20 46,XY,add(11)(q23)[4]/46,sl,del(2)(q13q31),del(9)(p13p22),
del(11)(q21q23)[3]/46,XY,inv(12)(p13q22)[6]/46,XY[7]
nuc ish(CD82x2),(ATMx1)[15/200]
nuc ish(pBR12,APAF1)x2[200/200]
nuc ish(D13S319x1),(LAMP1x2)[40/
250]
nuc ish(CCND1,IGH@)x2[205/205]
nuc ish(TP53,ERBB2)x2[200/200]
nuc ish(CDKN2Ax1)[70/200]
7.5
0
16.0
0
0
35.0
del chr13:45167078-76782310 (13q14.12q22.3)
del chr9:14515097-22847775 (9p22.3p21.3)
del chr2:95110968-151785533 (2q11.1q23.3)
del chr3:46141-33554787 (3p26.3p22.3)
del chr5:110467739-115587530 (5q22.1q23.1)
del chr6:85275259-106796313 (6q14.3q21)
del chr8:345060-111175147 (8p23.3q23.2)
del chr11:100299542-118463179 (11q22.1q23.3)
del chr14:105267349-105437150 (14q32.33q32.33)
dup chr17:43041299-78654742 (17q21.32q25.3)
31.6 Mb
8.3 Mb
56.7 Mb
33.5 Mb
5.1 Mb
21.8 Mb
110.8 Mb
18.2 Mb
170 kb
35.6 Mb
21 46,XY,del(11)(q13q23)[4]/46,sl,add(2)(p23),add(3)(p25),add
(8)(q24.1),add(12)(q22)[5]/45,sl,add(8)(q24.1),del(8)
(p11.2p21),-13,der(22)t(13;22)(q14;p11.2)[6]/46,XY[8]
nuc ish(CCND1,IGH@)x2[211/211]
nuc ish(D11Z1x2),(ATMx1)[163/207]
nuc ish(DDIT3)x2[244/244]
nuc ish(D13S319x1),(LAMP1x2)[27/
200]
nuc ish(D13S319x0),(LAMP1x2)[152/
200]
nuc ish(TP53x2),17cen(x2)[210/210]
0
78.7
0
13.5
76.0
0
del chr11:84811642-126916549 (11q14.1q24.2)
del chr13:46660529-49406099 (13q14.2q14.3)
del chr11:49408635-49590709 (11p11.12)
dup chr2:60466431-61759445 (2p16.1p15)
del chr6:55544176-78754776 (6p12.1q14.1)
del chr8:2530350-5909600 (8p23.2p23.2)
del chr8:39514037-39797061 (8p11.22p11.22)
del chr8:13967960-17118468 (8p22p22)
del chr8:115351618-116782788 (8q23.3q23.3)
del chr11:49408635-49590709 (11p11.12p11.12)
42.1 Mb
2.75 Mb
182.1 kb
1.3 Mb
23.2 Mb
3.4 Mb
768 kb
3.2 Mb
1.4 Mb
182 kb
22 N.D. nuc ish(D11Z1,ATM)x2[214/214] cells
nuc ish(DDIT3)x3[18/205]
nuc ish(D13S319x1),(LAMP1x2) [63/
200]
nuc ish(CCND1,IGH@)x2[214/215]
nuc ish(TP53x2),17cen(x2)[199/200]
0
8.8
31.5
0
0
dup chr12:74345-132289534
del chr13:48903923-49406099 (13q14.3q14.3)
del chr6:155195287-155551631 (6q25.2q25.2)
del chr14:105267349-105437150 (14q32.33q32.33)
del chr18:51018278-51378509(18q21.2q21.2)
Trisomy
502 kb
356 kb
170 Kb
IGH
360 kb
23 46,XX[20] nuc ish(D11Z1,ATM)x2[234/236]
nuc ish(DDIT3)x2[222/222]
nuc ish(D13S319,LAMP1)x2[203/204]
nuc ish(CCND1,IGH@)x2[210/210]
nuc ish(TP53x2),17cen(x2)[199/200]
0
0
0
0
0
del chr22:21330008-21570697 (22q11.22q11.22) 241 kb
† Nonspecific chromosome aberrations such as “add” or “del” were often redefined by the microarray results and are considered to have been detected.
§ Tetraploidy was not detected by microarray.
N.D. = Not Done.
Chr11 FISH [BAC 351G15 (ATM/11q22.3) and BAC 222Q13 (CD82/11p11.2) probes].
Chr12 FISH [12cen (pBR12) and APAF1/12q23 (BAC 210L7) probes].
Chr13 FISH [LSI D13S319 (13q14.3)/LSI LAMP1 (13q34), Vysis, Inc.].
Cyclin D1/IGH@ FISH [CCND1 (11q13)/IGH (14q32.3) probe, Vysis, Inc.].
Chr17 FISH [TP53 (17p13.1) BAC 199f11/ERBB2 (17q21.1) BAC 62n23 probes].
MLL/11q23 FISH [LSI MLL (11q23) probe, Vysis, Inc.].
MYC FISH LSI C-MYC (8q24.12-q24.13) probe Vysis, Inc.
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4Table 2 Cases in which microarray analysis did not detect aberrations identified by chromosome analysis or FISH
Case Karyotype FISH Percent Abnormal by FISH Array Results Size
3 47,XY,+12[3]/46,XY[16]/92,XXYY[1] nuc ish(CCND1,IGH@)x2 [202/202] 0 Arr(1-22)x2,(XY)x1
nuc ish(CD82,ATM)x2[199/200] 0
nuc ish(pBR12,APAF1)x3 [5/200] 2.5
nuc ish(D13S319,LAMP1)x2[204/204] 0
nuc ish(TP53,ERBB2)x2[200/200] 0
4 46,XY,del(4)(p?15.2),del(11)(q21q23.3),
add(14)(q32)[10]/46,XY[9]
nuc ish(ATMx1), (KAI1x2)[ 74/200] 37.0 del chr11:101900200-113746962 (11q22.2q23.2) 11.8 Mb
nuc ish(ATMx1),(KAI1x1)[8/200] 4.0
nuc ish(D13S319x1),(LAMP1x1)[31/235] 13.2
nuc ish(D13S319x1),(LAMP1x2) [110/235] 46.8 del chr13:48903923-49406099 (13q14.3q14.3) 502 kb
nuc ish(5’IGHVx1,3’IGHx1)[7/227] 3.1
nuc ish(5’IGHVx2,3’IGHx2)(5’IGHV sep 3’IGHx1)[35/227] 15.4
nuc ish(5’IGHVx1,3’IGHx2)(5’IGHV sep 3’IGHx1)[40/227] 17.6
nuc ish( (TP53,ERBB2)x2[250/250] 0
nuc ish(MYCx3)[ 116/200] 58.0 dup chr8:124436106-146015567 (8q21.13q24.3) 21.6 Mb
del chr4:16516563-30324345 (4p15.32p15.1) 13.8 Mb
del chr7:81021736-96580930 (7q21.11q21.3) 15.5 Mb
7 46,XY,t(14;19)(q32.3;q13.2)[9]/46,XY[11] nuc ish(CD82,ATM)x2[199/200] 0
nuc ish(pBR12,APAF1)x2[199/200] 0
nuc ish(D13S319,LAMP1)x2[243/243] 0
nuc ish(CCND1,IGH@)x2[200/200] 0
nuc ish(TP53x1),17cen(x2)[10/202] 5.0
del chr14:105267349-106339477 (14q32.33q32.33) 170 kb
del chr22:21330008-21570697 (22q11.22q11.22) 241 kb
8 46,XY,del(11)(q14q23)[4]/48,XY,+4,+
inv(?18)(q21q23)[3]/46,XY[13]
nuc ish(CD82x2),(ATMx1)[21/200] 10.5
nuc ish(Pbr12,APAF1)x2[ 199/200] 0
nuc ish(D13S319x1),(LAMP1x2)[90/201] 44.8 del chr13:47759453-49406099(13q14.2q14.3) 1.6 Mb
nuc ish(CCND1,IGH@)x2[200/200] 0
nuc ish(TP53,ERBB2)x2[199/200] 0
dup chr4:1-191273063 Trisomy
dup chr18:1-76117153 Trisomy
10 47,XY,+12[9]/46,XY[11] nuc ish(D11Z1x2),(ATMx3)[ 11/229] 4.8
nuc ish(DDIT3)x3[126/226] 55.8 up chr12:74345-132349534 Trisomy
nuc ish(D13S319,LAMP1)x2[199/200] 0
nuc ish(CCND1,IGH@)x2[200/200] 0
nuc ish(TP53x1),17cen(x2)[11/213] 5.2
del chr22:21044595-21570697 (22q11.22q11.22) 526 kb
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4Table 2 Cases in which microarray analysis did not detect aberrations identified by chromosome analysis or FISH (Continued)
16 Previous Sideline: 47,XX,t(2;14)
(p13;q32.1),+12[1]/46,XX[19]
nuc ish(pBR12,APAF1)x3[3/202] 1.5 Arr(1-22,X)x2
17 Previous Sideline: 45,XY,del(3)(q21q27),-8,
del(8)(p10),add(?9) (p13),del(11)(q13q23),
del(13)(q14q22),add(17)(p10)[1]/46,XY[30]
nuc ish(CD82x2),(ATMx1)[6/200] 3.0 del chr11:84811642-124583747 (11q14.1q24.2) 39.8 Mb
nuc ish(D13S319x1),(LAMP1x2)[44/243] 18.1 del chr13:46386690-57242066 (13q14.2q21.1) 10.9 Mb
nuc ish(D13S319x0),(LAMP1x1 or 2)[33/243] 13.6
nuc ish(TP53x1),(ERBB2x2) [17/200] 8.5
dup chr2:44073-60812692 (2p25.3p16.1) 60.8 Mb
del chr6:57972657-147822754 (6p11.2q24.3) 89.9 Mb
del chr9:9839207-27863525 (9p23p21.2) 18.0 Mb
18 46,XY,t(3;11)(q21;p15)[,
der(5)del(5)(q13q31)t(5;15)
(q31;q13),r(?7)(p22q?22),
der(15)t(5;15),-21[6]/46,XY[13]
nuc ish(CD82,ATM)x2[200/200] 0
nuc ish(pBR12,APAF1)x2[200 of 200] 0
nuc ish(D13S319,LAMP1)x1[27/200] 13.5
nuc ish(D13S319x1),(LAMP1x2)[82/200] 41.0
nuc ish(CCND1,IGH@)x2[228/228] 0
nuc ish(TP53,ERBB2)x2[195/200] 2.5
del chr3:66524310-71438751 (3p14.1p14.1) 4.9 Mb
del chr5:67408207-67790791 (5q13.1q13.1) 382 kb
del chr5:76836011-180616147 (5q14.1q35.3) 104 Mb
del chr7:2327342-54294538 (7p22.3p11.2) 54.2 Mb
del chr7:81021736-96580930 (7q21.11q21.3) 15.6 Mb
del chr7:102955780-158788150 (7q22.1q36.3) 55.8 Mb
del chr21:41514980-46912065 (21q22.3q22.3) 5.4 Mb
24 46,XY[20] nuc ish(D11Z1,ATM)x2[213/213] 0
nuc ish(DDIT3)x2[229/229] 0
nuc ish(D13S319,LAMP1)x1[15/203] 7.4 del chr13:48903923-49406099 (13q14.3q14.3) 502.2 kb
nuc ish(D13S319x1),(LAMP1x2)[155/203] 76.3
nuc ish(CCND1,IGH@)x2[223/223] 0
nuc ish(TP53x2),17cen(x2)[199/200] 0
25 N.D. uc ish(D11Z1,ATM)x2[212/213] 0 Arr(1-22,X)x2
nuc ish(DDIT3)x2[204/204] 0
nuc ish(D13S319x1),(LAMP1x2)[13/217] 6.0
nuc ish(D13S319x0),(LAMP1x2)[30/217] 13.8
nuc ish(D13S319x0),(LAMP1x2)[30/217] 0
nuc ish(TP53x2),17cen(x2)[199/200] 0
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4Specimens with concordance between microarray and
FISH/chromosome analyses
Fifteen of the 25 cases analyzed by microarray analysis
showed detection of all copy number abnormalities
identified by chromosome analysis and FISH (Table 1).
For example, in case 1 cytogenetic analysis identified a
single clonal abnormality [del(11)(q21q23.3] in six of 20
cells examined. FISH analysis detected deletion of a sin-
g l ea l l e l eo ft h eATM locus in 69% of the cells and bial-
lelic deletion in 14.5%. Microarray analysis identified
this deletion, defined the size (28.9 Mb) and refined the
interval involved (11q14.1q23.2), which included the
ATM locus (Figure 1A). Microarray analysis also identi-
fied a 1.8-Mb deletion at 13q14.2q14.3 that includes the
RB1 locus, with the clinically significant MIR16-1 and
MIR15A localized in the distal gap, which was not seen
by conventional analysis but was identified by FISH in
64.5% of cells analyzed (Figure 1B).
Additional complexity revealed by microarray analysis
In 15 of 25 (60%) cases, microarray analysis revealed
additional complexity. For example, case 2 had both a
der(3) and der(6) recognized by chromosome analysis,
each of which was associated with an inversion event
[der(3)del(3)(p13p21)inv(3)(p21p24), and der(6)del(6)
(q15q21)inv(6)(p21.3q23]. The microarray results for
chromosome 6 are shown in Figure 2. In addition to
detection of the deletion, copy loss was identified at each
of the inversion breakpoints. Gains at 1pter, 13qter and
20qter were also noted, as well as a terminal loss at 14q
including the IGH locus. FISH analysis detected a 13q14
deletion in 78.5% of cells, and microarray analysis identi-
fied a deletion at 13q14.3; however, BAC clone coverage
in the region is poor (Figure 3A, 3B). In case 15, microar-
ray analysis detected an ATM deletion, the sole abnorm-
ality identified by both chromosomes and FISH.
In four cases with new abnormalities, the aberrations
included a deletion within an interval defined as a puta-
tive CLL susceptibility locus. Case 1 showed a deletion at
11p11.2p11.12 with a single BAC clone showing apparent
homozygous deletion over the gene PTPRJ (Figure 1A).
Two additional cases (6 and 21) showed heterozygous
single-BAC deletions at 11p11.12, approximately 1.3 Mb
proximal to PTPRJ. The closest gene to this deletion is
FOLH1, which resides in a gap between the deletion and
the next most distal BAC contig. Case 2 had a 468.9-kb
deletion at 6q21.33. Two additional cases, 18 and 20,
showed large multi-megabase deletions that include the
susceptibility region mapped to 5q22q23.
Specimens with discordance between microarray and
FISH/chromosome analyses
Ten specimens showed discordance between microarray
results and prior FISH and/or chromosome analysis
(Table 2). Three specimens, cases 3, 16 and 25, had nor-
mal microarray results (Table 2). Case 3 showed three
cells out of 20 with trisomy 12 by chromosome analysis,
but was only 2.5% positive for trisomy 12 by FISH fol-
lowing assessment with the full CLL FISH panel. Case
16 was a sample submitted for assessment of residual
Figure 1 Microarray results for case 1. (A) Single-copy loss of probes at 11q14.1q11.23.2, approximately 28.9 Mb in size. This deletion interval
includes the ATM locus. Probes are ordered on the x axis according to physical mapping positions, with the most distal p-arm probes on the
left and the most distal q-arm probes on the right. The blue line represents the ratios for each clone from the first experiment (control/patient),
and the pink line represents the ratios for each clone obtained from the second experiment in which the dyes have been reversed (patient/
control). The yellow shaded region shows a deletion at 11p11.2p11.12 with a single BAC clone showing apparent homozygous deletion over the
gene PTPRJ. Results are visualized using Genoglyphix (Signature Genomics). (B) Single-copy loss of probes at 13q14.2q14.3, approximately 1.8 Mb
in size. This deletion interval includes the RB1 locus. Probes are arranged as in (A).
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Page 8 of 14disease and had previously been shown to exhibit tris-
omy 12. However, the specim e na n a l y z e di no u rs t u d y
showed the abnormality to be present in one cell of 20
by chromosome analysis and 1.5% by FISH (Table 2).
In several cases, microarray analysis failed to detect
aberrations that were identified by prior FISH and/or
chromosome analysis. For most of these cases abnorm-
alities detected by FISH and/or chromosome analysis
that were present in at least 10% of cells were detected
by microarray, whereas values below 10% were not likely
to be detected (Table 2). However, there were excep-
tions. Cases 4, 8, 10, 17 and 24 all yielded mixed results,
with detection of one or more abnormalities and a
concurrent failure to detect others. Microarray analysis
of cases 10, 17 and 24 confirmed all aberrations present
in more than 10% of the cells by FISH but failed to
detect most that scored below 10% on FISH (see Table
2). In case 8, FISH identified deletions at ATM (10.5%)
and 13q14 (44.8%), but the ATM alteration was not con-
firmed by array (Figure 4A, B). For comparison, chro-
mosome analysis of that same case had also identified
the ATM deletion, as well as trisomy for chromosomes
4 and 18 (3/20 cells). Although microarray analysis
failed to detect the ATM deletion, trisomy 4 and 18
were both detected (Figure 4C, D). Case 10 exhibited
trisomy 12 in 55.8% of cells by FISH and deletions of
Figure 2 Microarray characterization of a der(6)del(6)(q15q21)inv(6)(p21.3q23) in case 2. In addition to a del(6)(q15q21) (arrow), single-
copy losses were identified at each of the inversion breakpoints. Probes are arranged as in Figure 1A.
Figure 3 Microarray results for cases with 13q14 deletions identified by FISH reveal insufficient coverage for the detection of small
deletions. (A) Microarray plot for case 2. For this case, the CLL FISH panel showed ~78.5% of cells with a 13q14 deletion. A deletion was
detected by microarray analysis, but the extent of that deletion cannot be defined owing to insufficient coverage on the BAC array. (B)
Insufficient coverage for the BAC array does not permit determination of the involvement of MIR16-1 and MIR15A in the deletion shown in part
A. (C) Microarray plot for case 25. For this case, the CLL FISH panel showed ~20% of cells with a 13q14 deletion using a probe specific to MIR16-
1 and MIR15A. Insufficient BAC coverage on this array is likely responsible for the failed detection of a small deletion. Plots are arranged as in
Figure 1A.
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Page 9 of 14both ATM and TP53 at levels below 10%. Microarray
analysis was only able to detect the trisomy (Table 2,
Figure 5). For case 4, FISH-identified deletions of ATM,
13q14 and IGH all exceeded 10%, and all were detected
by array. However, monosomies for chromosomes 11
(4%), 13 (13.2%) and 14 (3.1%) that were detected by
FISH were not detected by array. In contrast, for case 9,
low-level deletions for both ATM (5.7%) and 13q14
(5.0%) were detected by microarray.
Chromosome analysis was not performed on case 25;
however, the CLL FISH panel showed ~20% of cells
with a 13q14 deletion, the majority showing biallelic
loss. The microarray results were normal, including the
BAC clones covering 13q14 (Figure 3C). Given the high
frequency of biallelic loss detected by FISH, it is surpris-
ing that the microarray failed to detect this abnormality.
For case 7, chromosome analysis identified t(14;19)
(q32.3;q13.2) in nine of 20 cells evaluated, and FISH
analysis with the CLL panel detected a TP53 gene
deletion in only 5% of cells. Microarray analysis was
normal with the exception of small gene-specific dele-
tions for IGL and IGH.T h eIGH deletion may be speci-
fically related to t(14;19)(q32.3;q13.2) translocation. The
translocation breakpoint on chromosome 19, represent-
ing the BCL3 gene, is not well covered on the microar-
ray, and the detection of a breakpoint-specific alteration
would not be expected. The fact that the TP53 gene
deletion seen by FISH was not detected is not surpris-
ing, because 5% is below the anticipated limits of micro-
array analysis.
For case 18, microarray results detected all abnormal-
ities detected by chromosome analysis but none of the
aberrations detected by FISH. Deletion 13q14 (41%),
monosomy 13 (13.5%) and TP53 deletion (2.5%) were all
undetected. One additional case, 23, had both normal
cytogenetics and normal results for the full CLL FISH
panel. The case was evaluated to determine whether
there were abnormalities below the resolution of routine
Figure 4 Microarray results for case 8 showing discordance between microarray and FISH. (A) Microarray analysis did not detect the
deletion at ATM that was identified in 10.5% of cells by FISH. (B) Microarray detected the 13q14 deletion that was present in 44.8% by FISH.
Microarray analysis also detected (C) trisomy 4 and (D) trisomy 18. Probes are arranged as in Figure 1A.
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Page 10 of 14assays. The only alteration detected was a small deletion
involving the IGL locus.
Detection of microarray abnormalities within a mosaic
tetraploid background
In two cases (11 and 14), microarray analysis identified
aberrations in cells shown by chromosome analysis to
represent mosaic tetraploidy. For case 11 (25% tetraploidy),
aberrations identified by conventional chromosome analy-
sis, which were seen in both diploid cells and also in tetra-
ploid cells following reduplication, were identified by
microarray (Figure 6). In contrast to case 11, cytogenetic
aberrations seen on cytogenetic analysis in case 14 (50%
tetraploidy) were confined to the tetraploid cell population.
The abnormalities were not present in the diploid cell
population. However, the abnormalities associated with
this specimen were also detected by aCGH with a total of
13 aberrations identified. As expected, the mosaic tetra-
ploidy was not detectable in either case.
Discussion
Several recent studies have suggested that microarrays
are likely to improve diagnostic and prognostic determi-
nations related to CLL, although it has not been deter-
mined how such data will best be used in conjunction
with established cytogenetic and FISH criteria. In this
study we evaluated 25 CLL samples by microarray ana-
lysis. All had prior FISH analysis for one or more
probes, and 23 cases had prior chromosome analysis
(Tables 1 and 2). Excluding three cases with normal
array results, 22 cases had abnormal microarray findings.
In 15 cases (60%), microarray analysis identified new
abnormalities not recognized by cytogenetic analysis and
FISH. These results demonstrate the clinical utility of
microarray analysis for the identification of cytogenetic
aberrations related to CLL. Of course, one should con-
sider the possibility of an underlying concurrent condi-
tion such as myelodysplastic syndromes (MDS).
However, for the majority of the cases in this study no
morphologic evidence of MDS was seen, and most had
extensive bone marrow or peripheral blood involvement
by CLL, so genetic changes are likely CLL related.
With several exceptions, microarray analysis was able
to identify abnormalities present in as few as 10% of
cells analyzed by chromosome analysis or FISH. The
sensitivity of detection for known abnormalities was
improved over the 30% that has been previously
reported for the analysis of CLL cases by others [10].
While prior experience with constitutional clinical cases
using this array suggests an average detection of
Figure 5 Microarray results for case 10 showing discordance between FISH and microarray results. (A) Microarray plot showing trisomy
12, which was in 55.8% of cells by FISH. (B, C) Normal microarray plots for (B) chromosome 11 and (C) chromosome 17. Probes are arranged as
in Figure 1A.
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Page 11 of 14approximately 20% mosaicism [16], in the current study
that limit of detection was closer to 10%, albeit with cer-
tain exceptions (Table 1 and 2).
Several cases had minimal or normal microarray
results that were surprising and may reflect inadequate
array clone coverage. Failure to detect the chromosome
13 alterations, particularly the 13q14 deletion, is unex-
pected based on the limits defined by other cases.
Microarray coverage may have been inadequate to con-
f i r mas m a l lg e n o m i cd e l e t i o n .T h eF I S Hp r o b er o u t i -
nely used in these studies maps in a gap telomeric to
t h eB A Cc l o n ec o v e r a g en e a rt h eRB1 locus. Smaller
d e l e t i o n si nC L Lc a s e sw i t h i nt h i sg a pt h a td on o t
include the RB1 locus, but do include the clinically rele-
vant MIR16-1 and MIR15A genes, have been described
[10]. For case 2, aCGH revealed deletion of a contig of
three BAC clones that reside between the RB1 gene and
MIR16-1 and MIR15A. Coverage was sufficient to
exclude the inclusion of the RB1 in the deletion, but as
with the previous case, this BAC array lacked sufficient
resolution to identify MIR16-1 and MIR15A deletion as
defined by FISH (Figure 3A-C). These results suggest
the need for higher density and specifically targeted cov-
erage for these critical regions of interest.
A similar circumstance was seen for ATM deletion
detection, which suggests that inadequate coverage in
addition to low-level representation provide a likely
explanation for the failure to detect these deletions
when seen by FISH. Although the Vysis FISH probe is
positioned directly over the ATM locus, the nearest
BAC contig to this locus on our constitutional array is
1.2 Mb proximal. Finally, although our microarray has
direct coverage over TP53, those cases in which detec-
tion was missed all had representation in less than 10%
of the nuclei by FISH.
BAC-based aCGH is not designed to optimally detect
differences in ploidy owing to inherent limitations in the
technology. Because equal quantities of diploid (control)
and triploid or tetraploid (specimen) DNA are com-
pared, in the absence of any additional abnormalities,
the total number of chromosomes represented in both
the specimen and control samples will be equivalent,
precluding the detection of tetraploidy. For constitu-
tional cases it has been shown that careful examination
of the sex chromosome ratios between the patient sam-
ple and the control can facilitate the detection of tri-
ploidy, but not tetraploidy, if the specimen has been run
against an opposite-sex control [17]. The detection of
triploidy or tetraploidy in oncology cases constitutes an
important challenge that is likely to suffer from the
same limitations described and may be further compli-
cated by the potential mosa i cn a t u r eo ft h ep l o i d y .
Furthermore, additional copy changes present within the
mosaic triploid/tetraploid cell population might be
masked by the dilution that effectively occurs in match-
ing DNA quantity to that of a control. In the case of tet-
raploidy, if a specific alteration in question is present at
two copies per cell as a result of chromosome replica-
tion without division (i.e., +12 × 2 in 4n cells), then the
ratio of one abnormal chromosome per homologous
pair is preserved. However, if that same alteration arose
as a single event within a tetraploid cell, then it is pre-
sent on only one of the four homologues (i.e., +12 × 1
in 4n cells). The log2 ratio for the latter specimen would
be approximately half that seen for the former.
While the detection of ploidy remains an issue beyond
the limits of the BAC microarray technologies, our
results demonstrate that microarray analysis can detect
additional aberrations in a known mosaic tetraploid
background. Two male cases in the current study, case
11 and case 14, showed mosaic tetrasomy by both FISH
and conventional cytogenetics. For case 11, tetrasomy
was seen in 25-35% of the cells, whereas for case 14
such cells constituted approximately 50% of cells. For
case 11, all of the aberrations identified by conventional
chromosome analysis were seen in near-diploid cells. In
contrast, the cytogenetic aberrations in case 14 identi-
fied by conventional chromosome analysis were con-
fined to the tetraploid cells, with all diploid cells
exhibiting a normal karyotype. As expected, aCGH was
not able to detect the presence of tetraploidy in either
specimen. However, for both samples, it was possible to
Figure 6 Microarray characterization of a sample compromised by mosaic tetraploidy (case 11). Despite the mosaic tetraploidy, deletions
and duplications of multiple chromosomal regions were identified. These are outlined in greater detail in Table 1. A whole-genome view is
displayed with chromosome 1 on the left and the sex chromosomes on the right. The sex chromosome pattern is consistent with a male
specimen run against a female control. Probes are arranged as in Figure 1A.
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netics and/or FISH and identify additional abnormalities
(Table 1, Figure 6).
Epidemiological studies suggest the existence of sus-
ceptibility loci for CLL, with large numbers of families
showing disease clustering, including large pedigrees
with inheritance consistent with dominantly acting
alleles [18-22]. In at least one study, risk for CLL was
estimated to be increased seven-fold in first-degree rela-
tives of CLL patients, while the risk for Hodgkin and
non-Hodgkin lymphoma was elevated two-fold in the
relatives of CLL patients [23,24]. Multipoint linkage ana-
lyses using an 11,560-SNP array identified the highest
linkage disequilibrium (LD) on chromosome 11p11,
with the same genomic interval demonstrating the high-
est multipoint heterogeneity LOD (HLOD) score [25].
Potential candidate genes mapping to this interval
include PTPRJ, MADD and DDB2.H L O Dv a l u e sa l s o
suggested possible loci at 5q22q23, 6p22, 10q25, and
14q32, all distinct from those regions commonly evalu-
ated in CLL. In another study analyzing 206 families
with a history of CLL, the most significant linkage was
established at chromosome 2q21.2, with a suggestion of
additional potential loci at 6p22.1 and 18q21.1 [26]. One
report described the refined mapping of a chromosome
13 CLL predisposition locus to a 3.7-Mb interval at
13q21.33q22.2; however, sequencing of 13 genes in the
region identified no germline mutations. Indeed, the
specific genes within any of these intervals that contri-
bute to CLL predisposition have yet to be elucidated.
The 11p11.2p11.12 deletion observed in case 1 in our
study is well delineated by sufficient BAC coverage on
t h ed i s t a lb o u n d a r yt oc o n c l u d et h a tPTPRJ,b u tn o t
MADD and DDB2, is deleted. PTPRJ encodes a type J
protein tyrosine phosphatase receptor that regulates cel-
lular proliferation and differentiation. The value for the
log2 ratio for this interval is -0.306, consistent with het-
erozygous deletion in all cells. Although we cannot
determine whether the deletion at 11p11.2p11.12 was
inherited or acquired, owing to the blinded nature of
this study, detection of the deletion of PTPRJ in a case
of CLL is intriguing. Two additional cases had single-
BAC deletions at 11p11.12, approximately 1.3 Mb from
the PTPRJ gene. In contrast, case 2 showed a 468.9-kb
deletion at 6p21.33 that includes the HLA-C and HLA-B
loci, which have been implicated in CLL predisposition
in the previous mapping studies [25,26]. Two additional
cases (18 and 20) showed deletions that include a pre-
viously identified susceptibility region at 5q22q23, but
these deletions were large multi-megabase alterations
not likely to have been inherited. The identification of
alterations at putative CLL predisposition loci in four
out of 25 samples represents an exceptionally high
detection rate for familial cases. However, all specimens
analyzed in this study were from patients referred to a
tertiary care center. Thus, there may be a bias in repre-
sentation toward the more severely affected end of the
CLL clinical spectrum, which may include a greater pro-
portion of inherited cases.
Finally, and not surprisingly, analysis of 25 cases with
this array platform revealed at least one abnormality
that is not related to cancer but is clinically relevant.
Microarray analysis revealed a heterozygous loss at
16p12.2, likely to be constitutional in nature. Patients
with such deletions have been seen previously in the
laboratory and are carriers for autosomal recessive hear-
ing loss type 22 (DFNB22) caused by an alteration in
the OTOA gene [27,28].
Conclusion
We have performed microarray analysis of 25 previously
diagnosed CLL cases using a microarray platform opti-
mized for the assessment of prenatal and postnatal
inherited disorders. The results demonstrate exception-
ally good resolution with the detection of low-level
mosaicism (~10%), most likely attributable to the robust
performance of the platform design. Moreover, 15 of the
cases (60%) revealed additional complexity or new
abnormalities not recognized during traditional analysis,
illustrating the potential of microarrays to detect altera-
tions with relevance and susceptibility to the acquired
neoplastic disease, and inherited alterations with rele-
vance to constitutional disorders. These results are con-
sistent with the notion that CLL could be incidentally
diagnosed during the course of constitutional microarray
analysis of an adult patient, the population with greatest
risk of presenting with this fairly prevalent and under-
diagnosed disorder. Importantly, discordant results
between cytogenetic analysis/FISH and microarray ana-
lysis in 10/25 (40%) of cases in this study demonstrate
the need for a broad but targeted microarray optimized
for the detection of cancer-related abnormalities.
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